|
[1]
|
Ostrom, Q.T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., et al. (2013) CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States 2006-2010. Neuro-Oncology, 15, ii1-ii56. http://dx.doi.org/10.1093/neuonc/not151
|
|
[2]
|
Louis, N., Ohgaki, H., Wiestler, O.D., Cavenee, W.K., Burger, P.C., Jouvet, A., et al. (2007) The 2007 WHO Classification of Tumours of the Central Nervous System. Acta Neuropathologica, 114, 97-109.
http://dx.doi.org/10.1007/s00401-007-0243-4
|
|
[3]
|
Ohka, F. Natsume, A. and Wakabayashi, T. (2012) Current Trends in Targeted Therapies for Glioblastoma Multiforme. Neurology Research International, 2012, Article ID: 878425.
|
|
[4]
|
Jemal, A., Siegel, R., Xu, J. and Ward, E. (2010) Cancer Statistics 2010. CA: A Cancer Journal for Clinicians, 60, 277-300. http://dx.doi.org/10.3322/caac.20073
|
|
[5]
|
Olson, J.J., Nayak, L., Ormond, D.R., Wen, P.Y., Kalkanis, S.N. and Ryken, T.C. (2014) The Role of Targeted Therapies in the Management of Progressive Glioblastoma. Journal of Neuro-Oncology, 118, 557-599.
http://dx.doi.org/10.1007/s11060-013-1339-4
|
|
[6]
|
Stupp, R., Mason, W.P., van den Bent, M.J., Weller, M., Fisher, B., Taphoorn, M.J.B., et al. (2005) Radiotherapy PlusConcomitant and Adjuvant Temozolomide for Glioblastoma. The New England Journal of Medicine, 352, 987-996.
http://dx.doi.org/10.1056/NEJMoa043330
|
|
[7]
|
Stupp, R., Hegi, M.E., Mason, W.P., van den Bent, M.J., Taphoorn, M.J., Janzer, R.C., et al. (2009) Effects of Radiotherapy with Concomitant and Adjuvant Temozolomide Versus Radiotherapy Alone on Survival in Glioblastoma in a Randomized Phase III Study: 5-Year Analysis of the EORTC-NCIC Trial. The Lancet Oncology, 10, 459-466.
http://dx.doi.org/10.1016/S1470-2045(09)70025-7
|
|
[8]
|
Burzynski, S.R. (1969) Investigations on Unknown Ninhydrin-Reacting Substances in Human Blood Serum. I. Attempts at Identification of Three Such Substances. Experientia, 25, 490-491.
http://dx.doi.org/10.1007/BF01900774
|
|
[9]
|
Burzynski, S.R. (1976) Antineoplastons: Biochemical Defense against Cancer. Physiological Chemistry and Physics, 8, 275-279.
|
|
[10]
|
Burzynski, S.R. (1986) Antineoplastons—History of the Research (I). Drugs under Experimental and Clinical Research, 12, 1-9.
|
|
[11]
|
Burzynski, S.R. (2004) The Present State of Antineoplaston Research (1). Integrative Cancer Therapies, 3, 47-58.
http://dx.doi.org/10.1177/1534735403261964
|
|
[12]
|
Burzynski, S.R. (2006) Treatments for Astrocytic Tumors in Children: Current and Emerging Strategies. Pediatric Drugs, 8, 167-168. http://dx.doi.org/10.2165/00148581-200608030-00003
|
|
[13]
|
Burzynski, S.R., Janicki, T.J., Burzynski, G.S. and Marszalek, A. (2014) The Response and Survival of Children with Recurrent Diffuse Intrinsic Pontine Glioma Based on Phase II Study of Antineoplastons A10 and AS2-1 in Patients with Brainstem Glioma. Child’s Nervous System, Published Online. http://dx.doi.org/10.1007/s00381-014-2401-z
|
|
[14]
|
Burzynski, S.R., Janicki, T.J., Burzynski, G.S. and Marszalek, A. (2014) A Phase II Study of Antineoplastons A10 and AS2-1 in Children with High-Grade Glioma. Final Report (Protocol BT-06), and Review of Recent Trials. Journal of Cancer Therapy, 5, 565-577.
http://dx.doi.org/10.4236/jct.2014.56065
|
|
[15]
|
Burzynski, S.R. (1986) Synthetic Antineoplastons and Analogs. Drugs of the Future, 11, 679-688.
|
|
[16]
|
Burzynski, S.R. (1988) Antineoplastons: Basic Research and Clinical Applications. Advances in Experimental and Clinical Chemotherapies, 6, 1-7.
|
|
[17]
|
Burzynski, S.R., Janicki, T.J. and Burzynski, G.S. (2014) A Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients with Recurrent Glioblastoma Multiforme. Final Report (Protocol BT-21). Journal of Cancer Therapy, in press.
|
|
[18]
|
Burzynski, S.R., Janicki, T.J., Burzynski, G.S. and Marszalek, A. (2014) A Phase II Study of Antineoplastons A10 and AS2-1 in Children with Recurrent, Refractory or Progressive Primary Brain Tumors. Final Report (Protocol BT-22). Journal of Cancer Therapy, in press.
|
|
[19]
|
Sturm, D., Witt, H., Hovestadt, V., Khuong-Quang, D.A., Jones, D.T., Konermann, C., et al. (2012) Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma. Cancer Cell, 22, 425-437. http://dx.doi.org/10.1016/j.ccr.2012.08.024
|
|
[20]
|
Kim, Y.W., Koul, D., Kim, S.H., Lucio-Eterovic, A.K., Freire, P.R., Yao, J., et al. (2013) Identification of Prognostic Gene Signatures of Glioblastoma: A Study Based on TCGA Data Analysis. Neuro-Oncology, 15, 829-839.
http://dx.doi.org/10.1093/neuonc/not024
|
|
[21]
|
Burzynski, S.R. and Patil, S. (2014) The Effect of Antineoplastons A10 and AS2-1 and Metabolites of Sodium Phenylbutyrate on Gene Expression in Glioblastoma Multiforme. Journal of Cancer Therapy, in press.
|
|
[22]
|
Brusilow, S.W., Danney, M., Waber, L.J., Batshaw, M., Burton, B., Levitsky, L., et al. (1984) Treatment of Episodic Hyperammonemia in Children with Inborn Errors of Urea Synthesis. The New England Journal of Medicine, 310, 1630-1634. http://dx.doi.org/10.1056/NEJM198406213102503
|
|
[23]
|
Phuphanich, S., Baker, S.D., Grossman, S.A., Carson, K.A., Gilbert, M.R., Fisher, J.D., et al. (2005) Oral Sodium Phenylbutyrate in Patients with Recurrent Malignant Gliomas: A Dose Escalation and Pharmacologic Study. Neuro-Oncology, 7, 177-182. http://dx.doi.org/10.1215/S1152851704000183
|
|
[24]
|
Baker, M.J., Brem, S., Daniels, S., Sherman, B. and Phuphanich, S. (2002) Complete Response of a Recurrent, Multicentric Malignant Glioma in a Patient Treated with Phenylbutyrate. Journal of Neuro-Oncology, 59, 239-242.
http://dx.doi.org/10.1023/A:1019905127442
|
|
[25]
|
Weller, M., Cloughesy, T., Perry, J.R. and Wick, W. (2013) Standards of Care for Treatment of Recurrent Glioblastoma—Are We There Yet? Neuro-Oncology, 15, 4-27.
http://dx.doi.org/10.1093/neuonc/nos273
|
|
[26]
|
Prados, M.D. (2014) “We Will Know if When We See It;” Bevacizumab and Glioblastoma. Neuro-Oncology, 16, 469-470. http://dx.doi.org/10.1093/neuonc/nou036
|
|
[27]
|
Geison, L. (1995) The Private Science of Louis Pasteur. Princeton University Press, Princeton.
|
|
[28]
|
Comfort, N. (2012) The Science of Human Perfection: How Genes Became the Heart of American Medicine. Yale University Press, New Haven.
http://dx.doi.org/10.12987/yale/9780300169911.001.0001
|
|
[29]
|
Kreisl, T.N., Kim, L., Moore, K., Duic, P., Royce, C., Stroud, I., et al. (2009) Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma. Journal of Clinical Oncology, 27, 740-745. http://dx.doi.org/10.1200/JCO.2008.16.3055
|
|
[30]
|
Friedman, S., Prados, M.D., Wen, P.Y., Mikkelsen, T., Schiff, D., Abrey, L.E., et al. (2009) Bevacizumab Alone and in Combination with Irinotecan in Recurrent Glioblastoma. Journal of Clinical Oncology, 27, 4733-4740.
http://dx.doi.org/10.1200/JCO.2008.19.8721
|
|
[31]
|
Chamberlain, M.C. and Johnston, S.K. (2010) Salvage Therapy with Single Agent Bevacizumab for Recurrent Glioblastoma. Journal of Neuro-Oncology, 96, 259-269. http://dx.doi.org/10.1007/s11060-009-9957-6
|
|
[32]
|
Burkhardt, J.K., Riina, H., Shin, B.J., Christos, P., Kesavabhotla, K., Hofstetter, C.P., et al. (2012) Intra-Arterial Delivery of Bevacizumab after Blood-Brain Barrier Disruption for the Treatment of Recurrent Glioblastoma: Progression-Free Survival and Overall Survival. World Neurosurgery, 77, 130-134. http://dx.doi.org/10.1016/j.wneu.2011.05.056
|
|
[33]
|
Raiser, J.J., Abrey, L.E., Lassman, A.B., Chang, S.M., Lamborn, K.R., Kuhn, J.G., et al. (2010) A Phase II Trial of Erlotinib in Patients with Recurrent Malignant Gliomas and Non-Progressive Glioblastoma Multiforme Postradiation Therapy. Neuro-Oncology, 12, 95-103.
http://dx.doi.org/10.1093/neuonc/nop015
|
|
[34]
|
Iwamoto, M., Lamborn, K.R., Robins, H.I., Mehta, M.P., Chang, S.M., Butowski, N.A., et al. (2010) Phase II Trial of Pazopanib (GW786034), and Oral Multi-Targeted Angiogenesis Inhibitor, for Adults with Recurrent Glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro-Oncology, 12, 855-861.
http://dx.doi.org/10.1093/neuonc/noq025
|
|
[35]
|
Galanis, E., Jaeckle, K.A., Maurer, M.J., Reid, J.M., Ames, M.M., Hardwick, J.S., et al. (2009) Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study. Journal of Clinical Oncology, 27, 2052-2058. http://dx.doi.org/10.1200/JCO.2008.19.0694
|
|
[36]
|
Galanis, E., Buchner, J.C., Maurer, M.J., Kreisberg, J.I., Ballman, K., Boni, J., et al. (2005) Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study. Journal of Clinical Oncology, 23, 5294-5304.
http://dx.doi.org/10.1200/JCO.2005.23.622
|
|
[37]
|
Sathornsumetee, S., Desjardins, A., Vredenburgh, J.J., McLendon, R.E., Marcello, J., Herndon, J.E., et al. (2010) Phase II Trial of Bevacizumab and Erlotinib in Patients with Recurrent Malignant Glioma. Neuro-Oncology, 12, 1300-1310.
|
|
[38]
|
Reardon, D.A., Desjardins, A., Vredenburgh, J.J., Gururangan, S., Friedman, A.H., Herndon, J.E., et al. (2010) Phase 2 Trial of Erlotinib Plus Sirolimus in Adults with Recurrent Glioblastoma. Journal of Neuro-Oncology, 96, 219-230.
http://dx.doi.org/10.1007/s11060-009-9950-0
|
|
[39]
|
Lu-Emerson, C., Norden, A.D., Drappatz, J., Quant, E.C., Beroukhim, R., Ciampa, A.S., et al. (2011) Retrospective Study of Dasatinib for Recurrent Glioblastoma after Bevacizumab Failure. Journal of Neuro-Oncology, 104, 287-291.
http://dx.doi.org/10.1007/s11060-010-0489-x
|
|
[40]
|
Reardon, D.A., Vredenburgh, J.J., Desjardins, A., Peters, K., Gururangan, S., Sampson, S.H., et al. (2011) Effect of CYP3A-Inducing Anti-Epileptics on Sorafenib Exposure: Results of a Phase II Study of Sorafenib Plus Daily Temozolomide in Adults with Recurrent Glioblastoma. Journal of Neuro-Oncology, 101, 57-66.
http://dx.doi.org/10.1007/s11060-010-0217-6
|
|
[41]
|
Friday, B., Anderson, S.K., Buckner, J., Yu, C., Giannini, C., Geoffroy, F., et al. (2012) Phase II Trial of Vorinostat in Combination with Bortezomib in Recurrent Glioblastoma: A North Central Cancer Treatment Group Study. Neuro-Oncology, 14, 215-221. http://dx.doi.org/10.1007/s11060-010-0217-6
|
|
[42]
|
Chang, S.M., Kuhn, J.G., Robins, H.I., Schold, S.C., Spence, A.M., Berger, M.S., et al. (1999) Phase II Study of Phenylacetate in Patients with Recurrent Malignant Glioma: A North American Brain Tumor Consortium Report. Journal of Neuro-Oncology, 17, 984-990.
|
|
[43]
|
Goel, L. and Mercurio, A.M. (2013) VEGF Targets the Tumour Cell. Nature Reviews Cancer, 13, 871-882.
http://dx.doi.org/10.1038/nrc3627
|
|
[44]
|
Prud’homme, G.J. and Glinka Y. (2012) Neuropilins Are Multifunctional Coreceptors Involved in Tumor Initiation, Growth, Metastasis and Immunity. Oncotarget, 3, 921-939.
|
|
[45]
|
Soker, S., Takashima, S., Miao, H.Q., Neufeld, G. and Klagsbrun, M. (1998) Neuropilin-1 Is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor. Cell, 92, 735-745.
http://dx.doi.org/10.1016/S0092-8674(00)81402-6
|
|
[46]
|
Zachary, I.C., Frankel, P., Evans, I.M. and Pellet-Many, C. (2009) The Role of Neuropilins in Cell Signalling. Biochemical Society Transactions, 37, 1171-1178. http://dx.doi.org/10.1042/BST0371171
|
|
[47]
|
Kolodkin, A.L., Levengood, D.V., Rowe, E.G., Tai, Y.T., Giger, R.J. and Ginty, D.D. (1997) Neuropilin Is a Semaphorin III Receptor. Cell, 90, 735-762. http://dx.doi.org/10.1016/S0092-8674(00)80535-8
|
|
[48]
|
Neufeld, G., Kessler, O. and Herzog, Y. (2002) The Interaction of Neuropilin-1 and Neuropilin-2 with Tyrosine-Kinase Receptors for VEGF. Advances in Experimental Medicine and Biology, 515, 81-90.
http://dx.doi.org/10.1007/978-1-4615-0119-0_7
|
|
[49]
|
Nakayama, M. and Berger, P. (2013) Coordination of VEGF Receptor Trafficking and Signaling by Coreceptors. Experimental Cell Research, 319, 1340-1347.
http://dx.doi.org/10.1016/j.yexcr.2013.03.008
|
|
[50]
|
Goel, L., Chang, C., Pursell, B., Leav, I., Lyle, S., Xi, .S., et al. (2012) VEGF/Neurophilin-2 Regulation of Bmi-1 and Consequent Repression of IGF-1R Define a Novel Mechanism of Aggressive Prostate Cancer. Cancer Discovery, 2, 906-921. http://dx.doi.org/10.1158/2159-8290.CD-12-0085
|
|
[51]
|
Lu, V., Chang, J.P., Parachoniak, C.A., Pandika, M.M., Aghi, M.K., Meyronet, D., et al. (2012) VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition Through a MET/VEGFR2 Complex. Cancer Cell, 22, 21-35.
http://dx.doi.org/10.1158/0008-5472.CAN-12-0995
|
|
[52]
|
Rizzolio, S., Rabinowicz, N., Rainero, E., Lanzetti, L., Serini, G., Norman, J., et al. (2012) Neuropilin-1-Dependent Regulation of EGF-Receptor Signaling. Cancer Research, 72, 5801-5811.
http://dx.doi.org/10.1158/0008-5472.CAN-12-0995
|
|
[53]
|
Grandclement, C., Pallandre, J.R., Degano, S.V., Viel, E., Bouard, A., Balland, J., et al. (2011) Neuropilin-2 Expression Promotes TGF-β1-Mediated Epithelial to Mesenchymal Transition in Colorectal Cancer Cells. PLoS ONE, 6, Article ID: e20444. http://dx.doi.org/10.1371/journal.pone.0020444
|
|
[54]
|
Ginka, Y., Stoilova, S., Mohammed, N. and Prud’homme, G.J. (2011) Neuropilin-1 Exerts Co-Receptor Function for TGF-β-1 on the Membrane of Cancer Cells and Enhances Responses to Both Latent and Active TGF-β. Carcinogenesis, 32, 613-621. http://dx.doi.org/10.1093/carcin/bgq281
|
|
[55]
|
West, C.G., Rees, L., Duchesne, S.J., Patey, C.J., Terry, J.E., Turnbull, J.E., et al. (2005) Interactions of Multiple Heparin Binding Growth Factors with Neuropilin-1 and Potentiation of the Acidity of Fibroblast Growth Factor-2. The Journal of Biological Chemistry, 280, 13457-13464.
http://dx.doi.org/10.1074/jbc.M410924200
|
|
[56]
|
Banerjee, S., Sengupta, K., Dhar, K., Mehta, S., D’Amore, P.A., Dhar, G., et al. (2006) Breast Cancer Cells Secreted Platelet-Derived Growth Factor-Induced Motility of Vascular Smooth Muscle Cells in Mediated Through Neuropilin-1. Molecular Carcinogenesis, 45, 871-880.
http://dx.doi.org/10.1002/mc.20248
|
|
[57]
|
Byzova, T.V., Goldman, C.K., Pampori, N., Thomas, K.A., Bett, A., Shattil, S.J., et al. (2000) A Mechanism for Modulation of Cellular Responses to VEGF: Activation of the Integrins. Molecular Cell, 6, 851-860.
|
|
[58]
|
Wey, S., Gray, M.J., Fan, F., Belcheva, A., McCarty, M.F., Stoeltzing, O., et al. (2005) Overexpression of Neuropilin-1 Promotes Constitutive MAPK Signaling and Chemoresistance in Pancreatic Cancer Cells. British Journal of Cancer, 93, 233-241. http://dx.doi.org/10.1038/sj.bjc.6602663
|
|
[59]
|
Staton, J., Dutta, S., Zhang, H., Polavaram, N.S., Leontovich, A.A., Honscheid, P., et al. (2013) Autophagy Control by the VEGF-C/NRP-2 Axis in Cancer and Its Implication for Treatment Resistance. Cancer Research, 73, 160-171.
http://dx.doi.org/10.1158/0008-5472.CAN-11-3635
|
|
[60]
|
Beck, B., Driessens, G., Goossens, S., Youssef, K.K., Kuchnio, A., Caauwe, A., et al. (2011) A Vascular Niche and a VEGF-Nrp1 Loop Regular the Initiation and Stemness of Skin Tumours. Nature, 478, 399-403.
http://dx.doi.org/10.1038/nature10525
|
|
[61]
|
Snuderl, M., Batista, A., Kirkpatrick, N.D., de Almodovar, C.R., Riedemann, L., Walsh, E.C., et al. (2013) Targeting Placental Growth Factor/Neuropilin 1 Pathway Inhibits Growth and Spread of Medulloblastoma. Cell, 152, 1065-1076.
http://dx.doi.org/10.1016/j.cell.2013.01.036
|
|
[62]
|
Ellis, L.M. and Hicklin, D.J. (2008) VEGF-Targeted Therapy: Mechanisms of Anti-Tumour Activity. Nature Reviews Cancer, 8, 579-591. http://dx.doi.org/10.1038/nrc2403
|
|
[63]
|
De Bacco, F., Casanova, E., Medico, E., Pellegatta, S., Orzan, F., Albano, R., et al. (2012) The MET Oncogene Is a Functional Marker of a Glioblastoma Stem Cell Subtype. Cancer Research, 72, 4537-4550.
http://dx.doi.org/10.1158/0008-5472.CAN-11-3490
|
|
[64]
|
Bottsford-Miller, J.N., Coleman, R.L. and Sood, A.K. (2012) Resistance and Escape from Antiangiogenesis Therapy: Clinical Implications and Future Strategies. Journal of Clinical Oncology, 30, 4026-4034.
http://dx.doi.org/10.1200/JCO.2012.41.9242
|
|
[65]
|
Wick, W., Weller, M., Weiler, M., Batchelor, T., Yung, A.W.K. and Platten, M. (2011) Pathway Inhibition: Emerging Molecular Targets for Treating Glioblastoma. Neuro-Oncology, 13, 566-579.
http://dx.doi.org/10.1093/neuonc/nor039
|
|
[66]
|
Chinnaiyan, P., Kensicki, E., Bloom, G., Prabhu, A., Sarcar, B., Kahali, S., et al. (2012) The Metabolomic Signature of Malignant Glioma Reflects Accelerated Anabolic Metabolism. Cancer Research, 72, 5878-5888.
http://dx.doi.org/10.1158/0008-5472.CAN-12-1572-T
|